Ophthalmic involvement in IgG4-related disease
Abstract
Introduction: IgG4-related ophthalmic disease (IgG4-ROD) presents a frequency of 11-58.8%. Few studies describe the disparities with patients with extraophthalmic IgG4-related disease (NOT IgG4-ROD). Objectives: describe the clinical, imaging, pathological characteristics, laboratory results, and treatment of IgG4-ROD characteristics; and compare them with those of the NOT IgG4-ROD patients. Materials and methods: a descriptive study was carried out on a cohort of 54 patients with ER-IgG4. 16 patients with IgG4-ROD and 38 with NOT IgG4-ROD were recruited. The data was analyzed with the SPSS Statistics 19 software. Results: IgG4-ROD predominated in women. 75% presented bilateral ophthalmic involvement. A history of asthma was associated with the NOT IgG4-ROD group (p=0,018). Patients with IgG4-ROD presented lower serum levels of IgE and total IgG, and the lacrimal gland was the most affected structure. Lymphoplasmacytic and eosinophilic infiltrates predominated, with storiform fibrosis being more frequent than non-storiform in the IgG4-ROD group Conclusions: although the results were similar to those previously reported, in disagreement with other series, we found a negative association between asthma and serum total IgG levels with EOR-IgG4 patients.References
I. Wallace ZS, Deshpande V, Mattoo H, et al. IgG4-related disease: baseline clinical and laboratory features in 125 patients with biopsy-proven disease. Arthritis Rheumatology Hoboken NJ 2015;67:2466-75.
II. Ebbo M, Paciente M, Grados A, Groh M, Desblaches J, Hachulla E, Saadoun D, Audia S, Rigolet A, Terrier B, et al. Ophthalmic manifestations in IgG4-related disease. Medicine (Baltimore) 2017;96(10):e6205.
III. Zhao Z, Mou D, Wang Z, et al. Clinical features and relapse risks of IgG4-related ophthalmic disease: a single-center experience in China. Arthritis Res Ther 2021;23,98.
IV. Gan L, Luo X, Fei Y, et al. Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients. BMC Ophthalmol 2021 Dec 27;21(1):447.
V. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol Jpn Rheum Assoc 2012;22:21-30.
VI. Umehara H, Okazaki K, Kawa S, et al.; Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare (MHLW) Japan. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD. Mod Rheumatol 2021 May;31(3):529-533.
VII. Wallace ZS, Naden RP, Chari S, Choi H, Della-Torre E, Dicaire JF, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Ann Rheum Dis 2020 Jan;79(1):77-87. VIII. Goto H, Takahira M, Azumi A; Japanese Study Group for IgG4-Related Ophthalmic Disease. Diagnostic criteria for IgG4-related ophthalmic disease. Jpn J Opthalmol 2015; 59(1):1-7.
VIII. Goto H, Takahira M, Azumi A; Japanese Study Group for IgG4-Related Ophthalmic Disease. Diagnostic criteria for IgG4-related ophthalmic disease. Jpn J Opthalmol 2015; 59(1):1-7.
IX. Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed) 1983 Jan 22;286(6361):266.
X. Culver EL, et al. Elevated serum IgG4 levels in diagnosis, treatment response, organ involvement, and relapse in a prospective IgG4-related disease UK cohort. Am J Gastroenterol 2016 May;111(5):733-43.
XI. Chan ASY, Mudhar H, et al. Serum IgG2 and tissue IgG2 plasma cell elevation in orbital IgG4-related disease (IgG4-RD): potential use in IgG4-RD assessment. Br J Ophtahlmol 2017 Nov;101(11):1576-1582.
XII. Wallace ZS, Zhang Y, Perugino CA, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis 2019 Mar;78(3):406-412.
XIII. Kubota T, Moritani S. Orbital IgG4-related disease: clinical features and diagnosis. ISRN. Rheumatol 2012; 2012:412896.
XIV. Zachary S, Wallace Z, Deshpande V, Stone JH. Ophthalmic manifestations of IgG4-related disease: single-center experience and literature review. Semin Arthritis Rheum 2014;43:806-817.
XV. Gan L, Luo X, Fei Y, Peng L, et al. Long-term outcomes of IgG4-related ophthalmic disease in a Chinese IgG4related disease cohort. Front Med 2021;8:784520.
XVI. Wang L, Zhang P, Zhang X, et al. Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease: a prospective study of 403 patients. Rheumatology 2019;58(5):820-830.
XVII. Stone JH, Zen Y, Deshpande V. IgG4-Related Disease. N Engl J Med 2012;366 (6):539-51.
XVIII. Wu A, Andrew NH, McNab AA, Selva D. Bilateral IgG4- related ophthalmic disease: a strong indication for systemic imaging. Br J Ophthalmol 2016;100(10):1409-11.
XIX. Gan L, Luo X, Fei Y, Peng L, et al. Ophthalmic involvement disparities in clinical characteristics of IgG4-related disease: a retrospective study of 573 patients. BMC Ophthalmol 2021 Dec 27;21(1):447.
XX. Tiegs-Heiden LJ, Eckel CH, Hunt FE, et al. Immunoglobulin G4-related disease of the orbit: imaging features in 27 patients. American Journal of Neuroradiology July 2014; 35(7):1393-1397.
XXI. Wong AJ, et al. IgG4 immunostaining and its implications in orbital inflammatory disease. PLoS One 2014;9(10):e109847.
XXII. Sato Y, Notohara K, Kojima M, Takata K, Masaki Y, Yoshino T. IgG4-related disease: historical overview and pathology of hematological disorders. Pathology International 2010;60(4):247-258.
XXIII. Khosroshahi A, Wallace ZS, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015;67(7):1688.
XXIV. Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015;74(6):1171. Epub 2015 Feb 9.
XXV. Wang L, Zhang P, Wang M, et al. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther 2018;20:65.
XXVI. Carruthers MN, Stone JH, Deshpande V, Khosroshahi A. Development of an IgG4-RD responder index. Int J Rheumatol 2012;259408.
Copyright (c) 2023 on behalf of the authors. Reproduction rights: Argentine Society of Rheumatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
